Abstract Library

#4194 Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well-differentiated pancreatic neuroendocrine tumors

Introduction: Temozolomide (TMZ), an alkylating agent, is an effective treatment used in multiple tumor types including advanced pancreatic neuroendocrine tumors (PanNET). In glioblastomas, TMZ induces a hypermutator and hyperprogressor phenotype in a subset of patients through MMR deficiency. In advanced colon cancer, TMZ priming increases tumor mutational burden (TMB), favouring immunotherapy efficacy.

Conference:

Presenting Author: de Mestier L

Authors: de Mestier L, Cohen D, de Rycke O, Masliah Planchon J, Fleischmann Z,

Keywords: temozolomide, hypermutation, pancreatic neuroendocrine tumor,

#3639 Tumor uptake on 18FDOPA PET/CT is a strong prognostic factor in patients with metastatic small intestine neuroendocrine tumors (siNETs) – A GTE study

Introduction: 18FDOPA PET/CT has high diagnostic performances for siNETs. Its prognostic role is unknown.

Conference:

Presenting Author: de Mestier L

Authors: de Rycke O, Imperiale A, Perrier M, Bando-Delaunay A, Mennetrey C,

Keywords: FDOPA PET/CT, prognosis, small intestine NETs,

#3627 Early prediction of the efficacy of 177Lu-DOTATATE in patients with metastatic neuroendocrine tumors

Introduction: PRRT has a major place in the therapeutic strategy of metastatic NETs. Its efficacy is generally evaluated after four cycles, with no early predictor identified to date. During each PRRT cycle, 177Lu-related gamma emissions can be measured by post-PRRT scintigraphy.

Conference:

Presenting Author:

Authors: Bando-Delaunay A, de Rycke O, Hentic O, Leclerc P, Allouch A,

Keywords: PRRT, scintigraphy, prediction, response,

#3072 Rb and p53 Status Determination by Immunochemistry Is Complementary in Routine Practice to Genetic Testing of Neuroendocrine Neoplasms

Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Chen R, Lacroix L, De Rycke O, Lacombe C, Cazes A,

Keywords: rb, p53, aggressive neuroendocrine tumors, biomarker,

#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)

Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C,

Keywords: alkylating agents, pancreatic NET, re-challenge, chemotherapy,